ASCO
Refine search
Pharmaceutical
Data revealed at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting on Saturday offered a promising signal for AstraZeneca’s antibody drug conjugates (ADC) platform. 4 June 2018
Biosimilars
As the American Society for Clinical Oncology (ASCO) conference got underway on Friday, Samsung Bioepis revealed the results of a one-year follow-up study on SB3, its biosimilar alternative to Roche's blockbuster breast and stomach cancer treatment Herceptin (trastuzumab). 1 June 2018
Pharmaceutical
This week, cancer patients, oncologists and investors alike look ahead to the annual meeting of the American Society of Clinical Oncology (ASCO), which kicks off in Chicago on Friday. 29 May 2018
Biotechnology
Shares of US biotech Loxo Oncology leapt 21% to $167.53 after the firm released an abstract of early-stage data for its RET inhibitor LOXO-292. 18 May 2018
Pharmaceutical
In an Expert View piece, Annie Sullivan, director of corporate social media at Anglo-Swedish pharma major AstraZeneca, discusses the company’s novel approach of being 'a better social media citizen' and how its adoption of this strategy at the ASCO Annual Meeting in 2017 may help evolve the role of pharma on social media. 31 July 2017
Biotechnology
At an unusually quiet annual meeting of the American Society of Clinical Oncology, Joanne Lager and Israel Lowy, the oncology heads of Sanofi (Euronext: SAN) and Regeneron (Nasdaq: REGN), found time to speak with The Pharma Letter to discuss progress in their long-standing collaboration. 12 June 2017
Biotechnology
With so much of the exciting data at ASCO 2017 again surrounding cancer immunotherapies, The Pharma Letter finds confidence that more will follow in the footsteps of Merck & Co's Keytruda (pembrolizumab). 8 June 2017
Pharmaceutical
Swiss pharma giant Roche has released results from a pivotal trial comparing Alecensa with the standard of care in lung cancer, which show a marked improval in progression-free survival. 6 June 2017
Pharmaceutical
Tagrisso (osimertinib), the potential new standard-of-care for locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), also shows efficacy in patients with disease progression to central nervous system (CNS) metastases, according to new evidence reported at ASCO 2017. 6 June 2017
Biotechnology
As the annual meeting of the American Society of Clinical Oncology enters its final day, US biotech major Celgene has released data on two of its co-development programs exploring T cell therapies. 6 June 2017
Biotechnology
Hutchison China MediTech has announced results from its pivotal Phase III trial of fruquintinib, its novel vascular endothelial growth factor receptor (VEGFR) kinase inhibitor in an oral presentation at ASCO 2017. 6 June 2017
Pharmaceutical
Taking three-month breaks during long-term treatment with letrozole did not reduce the risk of recurrence of breast cancer compared with taking the aromatase inhibitor continuously for five years among postmenopausal women with hormone-sensitive early breast cancer who had already completed four to six years of therapy. 5 June 2017
Biotechnology
Swiss pharma giant Roche presented data showing that fewer patients with HER2-positive breast cancer see their disease return after adding Perjeta (pertuzumab) to Herceptin (trastuzumab) and chemotherapy at ASCO 2017 on Monday. 5 June 2017
Biotechnology
America’s Merck & Co will today present an additional five months of follow-up data on Keytruda in combination with pemetrexed and carboplatin (pem/carbo), in the first-line setting. 5 June 2017
Pharmaceutical
Privately-held German pharma Boehringer Ingelheim has presented encouraging Phase II survival data for nintedanib in malignant pleural mesothelioma (MPM) at ASCO 2017. 5 June 2017
Pharmaceutical
At the annual meeting of the American Society of Clinical Oncology, Japanese pharma major Eisai has released data from a Phase III study into Lenvima as a first-line liver cancer therapy. 5 June 2017
Biotechnology
US biotech Amgen on Sunday announced new data from the Xgeva (denosumab) Phase III ‘482 study, the largest international multiple myeloma trial ever conducted. 4 June 2017
Pharmaceutical
In what could be one of the most significant advances announced at the 2017 ASCO Annual Meeting, AstraZeneca has presented the first positive Phase III data on a PARP inhibitor beyond ovarian cancer. 4 June 2017
Pharmaceutical
US pharma major Eli Lilly has added to its body of data on abemaciclib in breast cancer as it seeks to gain ground on rivals in the cyclin-dependent kinase (CDK) 4 and 6 inhibitor space. 4 June 2017
Biotechnology
US biotech Loxo Oncology revealed at the American Society of Clinical Oncology (ASCO) meeting in Chicago that it will be seeking US Food and Drug Approval for its for larotrectinib as a treatment for patients with TRK fusion-positive tumors along with presenting new data showing that three-quarters of participants in a combined analysis responded to the drug. 4 June 2017
Biotechnology
Taiwanese biotech PharmaEssentia is preparing to seek an expanded US label for its long-acting interferon Besremi (ropeginterferon alfa-2b) following new late-stage data that show the therapy outperforms anagrelide in treating essential thrombocythaemia (ET) after hydroxyurea failure. 3 June 2025
Pharmaceutical
Detailed results from the Phase III OASIS-4 study have found that Bayer’s elinzanetant showed a statistically significant reduction in the frequency of moderate to severe vasomotor symptoms (VMS, also known as hot flushes) from baseline to week four and 12 compared to placebo, in women taking endocrine therapy to prevent hormone receptor (HR+) breast cancer. 2 June 2025
Pharmaceutical
Positive results from the SERENA-6 Phase III trial have shown that AstraZeneca’s camizestrant alongside a cyclin-dependent kinase (CDK) 4/6 inhibitor (palbociclib, ribociclib or abemaciclib) led to a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS). 2 June 2025
Biotechnology
The Alliance for Clinical Trials in Oncology has announced results from ATOMIC, a Phase III trial evaluating standard chemotherapy alone or combined with Roche’s Tecentriq (atezolizumab) in patients who have surgically resected stage III colon cancer and deficient deoxyribonucleic acid (DNA) mismatch repair (dMMR). 2 June 2025
Biotechnology
With ASCO 2025 drawing toward its close in Chicago, Amsterdam-based biotech Avidicure is entering the spotlight with its first public data on a new class of cancer immunotherapies. The company’s lead program, AVC-S-101, is designed to target TROP2 in non-small cell lung cancer (NSCLC) and other solid tumors. 2 June 2025
Biotechnology
US biotech Regeneron Pharmaceuticals has announced detailed analyses from the Phase III C-POST trial, which evaluated PD-1 inhibitor Libtayo (cemiplimab) in patients with high-risk cutaneous squamous cell carcinoma (CSCC) after surgery. 2 June 2025
Biotechnology
AstraZeneca has reported positive findings from its Phase III MATTERHORN trial, spotlighting the potential of its immunotherapy Imfinzi (durvalumab) to significantly delay disease progression in patients with early-stage and locally advanced gastric and gastroesophageal junction (GEJ) cancers. 2 June 2025
Pharmaceutical
Arcus Biosciences is setting the stage for a high-stakes Phase III showdown in kidney cancer, after early results showed that nearly half of patients treated with its experimental therapy had a confirmed response. 2 June 2025
Pharmaceutical
US drugmaker Protagonist Therapeutics and Japan’s Takeda Pharma announced detailed results from the Phase III, randomized, placebo-controlled VERIFY study evaluating rusfertide in patients with polycythemia vera (PV), which met the primary and all key secondary endpoints. 2 June 2025
Pharmaceutical
Arvinas and Pfizer today announced detailed results from the Phase III VERITAC-2 clinical trial (NCT05654623) evaluating vepdegestrant monotherapy versus fulvestrant in adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer (MBC) whose disease progressed following prior treatment with cyclin-dependent kinase (CDK) 4/6 inhibitors and endocrine therapy. 2 June 2025
Pharmaceutical
US pharma giant Pfizer on Saturday announced statistically-significant and clinically-meaningful survival results from the Phase III BREAKWATER trial evaluating Braftovi (encorafenib) in combination with cetuximab (marketed as Erbitux) and mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) in patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation. 2 June 2025
Biotechnology
Daiichi Sankyo and AstraZeneca have released detailed Phase III results that could help position their HER2-targeting drug Enhertu (trastuzumab deruxtecan) as the second-line standard of care for advanced gastric cancer. 2 June 2025
Biotechnology
In the run up to the 2025 annual ASCO meeting, IMUNON (Nasdaq: IMNN) is moving into a Phase III trial with its lead candidate IMNN-001. We interviewed president and chief executive Stacy Lindborg on the long path to this moment—and what may lie ahead in the evolving ovarian cancer treatment landscape. 28 May 2025
Pharmaceutical
Germany’s Merck KGaA today announced the presentation of detailed positive results from Part 1 of the global Phase III MANEUVER trial evaluating pimicotinib, a potentially best-in-class investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics, in the treatment of patients with tenosynovial giant cell tumor (TGCT). 28 May 2025
Biotechnology
French biotech ImCheck Therapeutics is preparing to showcase encouraging interim results for its investigational monoclonal antibody ICT01 at the 2025 ASCO Annual Meeting, highlighting the compound’s potential to improve outcomes in acute myeloid leukemia (AML) patients not eligible for intensive chemotherapy. 27 May 2025
Pharmaceutical
Verastem Oncology has unveiled updated early-stage data from its RAMP 205 trial in metastatic pancreatic cancer, bolstering its efforts to broaden use of its dual-drug regimen, Avmapki Fakzynja Co-Pack, beyond its recently approved indication in a rare form of ovarian cancer. 23 May 2025
Pharmaceutical
Japanese drugmaker Astellas and US pharma giant Pfizer have announced longer-term follow-up results from an open-label extension of the Phase III ARCHES study. 23 May 2025
Biotechnology
Among the companies displaying the strength of Chinese research in oncology at the 2025 ASCO Annual Meeting will be Hutchmed. 23 May 2025
Biotechnology
Swiss pharma major Roche has reported updated results from its Phase III STARGLO trial, showing that a fixed-duration regimen of Columvi (glofitamab) combined with gemcitabine and oxaliplatin (GemOx) continues to deliver a notable survival benefit for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). 23 May 2025
Pharmaceutical
The oncology community’s biggest gathering returns to Chicago from May 30 to June 3, and all signs suggest the 2025 ASCO Annual Meeting will be a watershed moment. 23 May 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze